Effects of Empagliflozin on Cardiovascular Mortality by Prevalent or Incident Heart Failure in EMPA-REG OUTCOME

28 August 2016 (17:15 - 17:23)

Organised by:

Slides

Sign in for access options

About the speaker

Doctor David Fitchett

St. Michael's Hospital, Toronto (Canada)

6 More presentations in this session

Presentation thumbnail

Prognostic implications of left ventricular global longitudinal strain in heart failure patients with narrow QRS treated with cardiac resynchronization therapy: analysis of the EchoCRT trial

Professor J. Bax (Leiden, NL)

Presentation thumbnail

Long-term Performance of a Transcatheter Pacing System: 12 Month Results From the Micra Global Clinical Trial

Doctor P. Ritter (Bordeaux, FR)

Presentation thumbnail

Association between risk reduction in cardiovascular deaths or hospitalizations and CRT optimization using the SonR contractility sensor in subgroups of patients: RESPOND-CRT Trial update

Professor J. Brugada Terradellas (Barcelona, ES)

Presentation thumbnail

Effects of empagliflozin on overall heart failure burden in EMPA-REG OUTCOME

Doctor D. Fitchett (Toronto, CA)

Presentation thumbnail

Echocardiographic Progression and Effects of Etiologic Treatment in Chagas Cardiomyopathy: A BENEFIT Trial Echocardiographic Sub-Study

Associate Professor A. Schmidt (Ribeirao Preto, BR)

Access the full session

Session thumbnail

Clinical Trial Update Heart failure and Pacing

The Event

ESC Congress 2016

28 August 2016 17:15 CET

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources